Brokerages Set DaVita Inc. (NYSE:DVA) Target Price at $157.00

Shares of DaVita Inc. (NYSE:DVA) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $157.00.

Several research analysts have recently issued reports on the stock. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial raised their target price on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Finally, UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th.

DaVita Stock Up 3.8 %

Shares of NYSE:DVA opened at $163.56 on Thursday. DaVita has a 12 month low of $71.51 and a 12 month high of $163.59. The company’s 50-day moving average price is $145.17 and its two-hundred day moving average price is $139.91. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The firm has a market cap of $13.72 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.90 and a beta of 0.87.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.08 EPS. As a group, research analysts forecast that DaVita will post 9.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at $12,137,038.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares in the company, valued at $36,299,008.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 113,601 shares of company stock worth $17,525,449. Company insiders own 2.00% of the company’s stock.

Institutional Trading of DaVita

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of DaVita in the fourth quarter valued at approximately $30,000. Principal Securities Inc. acquired a new position in DaVita during the fourth quarter worth $37,000. Family Firm Inc. acquired a new position in DaVita during the second quarter worth $43,000. Finally, Versant Capital Management Inc increased its holdings in DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after buying an additional 155 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.